Skip to content
10-Q

Quarterly Report

Semnur Pharmaceuticals, Inc. SMNR SMNRW

0001193125-26-221896

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 25, 2026 230.21M sh
Shares Diluted Q1 2026 · Mar 31, 2026 230.21M sh
Shares Diluted Q1 2026 · Mar 31, 2025 200M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.67M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$399K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $103K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $20K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$25.33M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$20.75M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 −$43.45M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$42.78M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.38M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.17M
Total Liabilities Q1 2026 · Mar 31, 2026 $27.3M
Total Liabilities Q1 2026 · Dec 31, 2025 $22.1M
Current Assets Q1 2026 · Mar 31, 2026 $1.22M
Current Assets Q1 2026 · Dec 31, 2025 $596K
Total Assets Q1 2026 · Mar 31, 2026 $1.97M
Total Assets Q1 2026 · Dec 31, 2025 $1.35M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.02
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.01
Eps Basic Q1 2026 · Mar 31, 2026 −$0.02
Eps Basic Q1 2026 · Mar 31, 2025 −$0.01
Sga Expense Q1 2026 · Mar 31, 2026 $3.31M
Sga Expense Q1 2026 · Mar 31, 2025 $478K
Rd Expense Q1 2026 · Mar 31, 2026 $1.27M
Rd Expense Q1 2026 · Mar 31, 2025 $187K
Net Income Q1 2026 · Mar 31, 2026 −$4.58M
Net Income restated Q1 2026 · Mar 31, 2025 −$665K
Operating Income Q1 2026 · Mar 31, 2026 −$4.58M
Operating Income restated Q1 2026 · Mar 31, 2025 −$665K